Targeted
Immuno-Oncology Platform

Targeted Immuno-Oncology Platform

Therapy Indication Partners Discovery Pre-Clinical Phase I Phase II
ACT-901
(AFP + paclitaxel) 		Targeted Immuno-Oncology
Solid and liquid tumors 		Collaboration University Health Network
 
ACT-902
(AFP + thapsigargin) 		Targeted Immuno-Oncology
Solid and liquid tumors 		Collaboration University Health Network
 
ACT-903
(AFP + linker + maytansine) 		Targeted Immuno-Oncology
Solid and liquid tumors 		Collaboration Abzena
 

Lead Assets

ACT-901 (AFP + paclitaxel)

  • Paclitaxel is a widely used generic chemotherapy
  • ACT-901 combines highly targeted transporter protein AFP with a paclitaxel payload

ACT-902 (AFP + thapsigargin)

  • Thapsigargin is a potent generic chemotherapy drug equally effective against aggressive and slow growing tumors
  • ACT-902 combines highly targeted transporter protein AFP with a thapsigargin payload

ACT-903 (AFP + linker + maytansine)

  • Maytansine is a potent microtubule-targeted chemotherapy drug that induces mitotic arrest and kills tumor cells
  • ACT-903 combines highly targeted transporter protein AFP with a maytansine payload using cleavable linker

Targeted Immuno-Oncology

Alpha Fetoprotein (AFP)

  • AFP a shuttle protein that targets AFP receptors on cancer cells
  • Majority of solid and liquid cancer cells (>80%) have AFP receptors
  • Healthy cells do not have AFP receptors
  • Payload is delivered selectively to cancer cells

Preparation of ACT-901 (Taxol Solubilization)

Benefits

  • Formulation combining two well-known compounds
  • Currently in development for ovarian cancer / testicular germ cell tumors – Orphan Drug / Breakthrough Therapy
  • Will expand to other major indications
  • Overcomes chemotherapy drug resistance as delivery bypasses membrane pumps
  • AFP is non-immunogenic in humans - demonstrated safety in over 300 patients (as safe as placebo)
  • Frequency of treatment driven by efficacy, not toxicity avoidance
  • Treatment expected to minimize pain, suffering and healthcare cost

Target Product Profile

  • Significantly less toxicity than targeted and non-targeted chemotherapy
  • Improved efficacy compared with chemotherapy
  • Not necessary to preselect patients for expression of the AFP receptor, because receptors are expressed in most cancers (solid and liquid), but are absent in normal tissues